3 ASX 200 healthcare shares to buy with 35% to 103% upside ahead

Telix reported 19% year-on-year Q3 revenue growth and reaffirmed full-year guidance, yet its shares have fallen about 19% since last Tuesday. The divergence highlights company-specific volatility in ASX healthcare rather than broad market stress. With no directly mapped symbol in the asset list, the read-through is limited for the wider market.